Literature DB >> 23119111

Tumor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK/T-cell lymphoma, nasal type.

Junshik Hong1, Sanghui Park, Hae Lim Baek, Joo Hyun Jung, Il Gyu Kang, Sun Jin Sym, Jinny Park, Jeong Yeal Ahn, Eun Kyung Cho, Seon Tae Kim, Dong Bok Shin, Jae Hoon Lee.   

Abstract

Extranodal natural killer/T-cell lymphoma, nasal type (nasal ENKTL) is a distinct clinicopathologic entity of lymphoid tumors with variable size and differentiation of tumor cells. Nasal ENKTL is related to infection of the tumor cells with Epstein-Barr virus (EBV) and virtually all cases contain monoclonal episomal EBV DNA and detectable EBV encoded small nuclear RNAs (EBERs). Several clinical factors are known for their relation to the prognosis, but histopathologic prognostic factors of nasal ENKTL have not yet been well established. We evaluated the prognostic value of the longest nuclear diameter of EBER+ tumor cells (NDTC) along with the result of CD30 expression. Twenty two patients with newly diagnosed nasal ENKTL were evaluated regarding clinicopathologic characteristics. NDTC was measured using a computerized image analysis system. The results were expressed as the mean diameter of ≥ 50 cells in a patient. Median of the mean NDTC of the patients was 7.32 μm (5.15-11.27). Patients with larger mean NDTC (≥ 7.35 μm) had a poorer event-free survival (EFS) than those with smaller mean NDTC (<7.35 μm; p = 0.024) and had a tendency of inferior overall survival (OS) (p = 0.08). Patients with CD30 expression had a inferior EFS (p = 0.018) and OS (p = 0.011) compared those without CD30 expression. The NDTC of EBV infected tumor cell and CD30 expression had relation to survival in the current exploratory analysis.

Entities:  

Keywords:  CD30; Extranodal NK/T-cell lymphoma; epstein-barr virus; nasal type; nuclear diameter; prognosis

Mesh:

Substances:

Year:  2012        PMID: 23119111      PMCID: PMC3484496     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  29 in total

1.  The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience.

Authors:  J Rodríguez; E Conde; A Gutiérrez; R Arranz; A León; J Marín; M Bendandi; C Albo; M D Caballero
Journal:  Ann Oncol       Date:  2007-01-17       Impact factor: 32.976

2.  Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment.

Authors:  G E Kim; J H Cho; W I Yang; E J Chung; C O Suh; K R Park; W P Hong; I Y Park; J S Hahn; J K Roh; B S Kim
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

3.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

Authors:  N L Harris; E S Jaffe; J Diebold; G Flandrin; H K Muller-Hermelink; J Vardiman; T A Lister; C D Bloomfield
Journal:  J Clin Oncol       Date:  1999-12       Impact factor: 44.544

Review 4.  Natural killer cell neoplasm: biology and pathology.

Authors:  Maria Francisca Ham; Young-Hyeh Ko
Journal:  Int J Hematol       Date:  2010-12-07       Impact factor: 2.490

5.  Angiocentric nasal T/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients.

Authors:  A Avilés; N R Díaz; N Neri; S Cleto; A Talavera
Journal:  Clin Lab Haematol       Date:  2000-08

6.  Different prognostic factors for survival in acute and lymphomatous adult T-cell leukemia/lymphoma.

Authors:  Brady Beltran; Pilar Quiñones; Domingo Morales; Esther Cotrina; Jorge J Castillo
Journal:  Leuk Res       Date:  2010-09-15       Impact factor: 3.156

7.  Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.

Authors:  Céline Bossard; Karim Belhadj; Felix Reyes; Nadine Martin-Garcia; Françoise Berger; Jean Alain Kummer; Josette Brière; Anne-Catherine Baglin; Stéphane Cheze; Jacques Bosq; Vincent Ribrag; Christian Gisselbrecht; Nicolas Mounier; Philippe Gaulard
Journal:  Blood       Date:  2006-10-31       Impact factor: 22.113

8.  Immunohistochemical characterization of nasal-type extranodal NK/T-cell lymphoma using a tissue microarray: an analysis of 84 cases.

Authors:  Erich J Schwartz; Hernan Molina-Kirsch; Shuchun Zhao; Robert J Marinelli; Roger A Warnke; Yasodha Natkunam
Journal:  Am J Clin Pathol       Date:  2008-09       Impact factor: 2.493

9.  Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type.

Authors:  S J Kim; B S Kim; C W Choi; J Choi; I Kim; Y-H Lee; J S Kim
Journal:  Ann Oncol       Date:  2007-08       Impact factor: 32.976

10.  Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma.

Authors:  W Y Kim; Y K Jeon; T M Kim; J E Kim; Y A Kim; S-H Lee; D-W Kim; D S Heo; C-W Kim
Journal:  Ann Oncol       Date:  2009-06-19       Impact factor: 32.976

View more
  12 in total

1.  Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin.

Authors:  Hee Kyung Kim; Seong Mi Moon; Ji Hoon Moon; Jee Eun Park; Seonggyu Byeon; Won Seog Kim
Journal:  Blood Res       Date:  2015-12-21

2.  The cell body space occupied by the nucleus during the cell differentiation in human lymphocytic, granulocytic and erythroid cell lineages.

Authors:  K Smetana; H Klamová; D Mikulenková; J Čermák; P Otevřelová; J Karban; M Trněný
Journal:  Physiol Res       Date:  2021-09-10       Impact factor: 1.881

Review 3.  Primary spleen extranodal NK/T cell lymphoma, nasal type, with bone marrow involvement and CD30 positive expression: a case report and literature review.

Authors:  Qinghua Cao; Yan Huang; Ziyin Ye; Ni Liu; Shuhua Li; Tingsheng Peng
Journal:  Diagn Pathol       Date:  2014-09-03       Impact factor: 2.644

4.  CD30 expression is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type.

Authors:  Pengfei Li; Li Jiang; Xinke Zhang; Jun Liu; Hua Wang
Journal:  BMC Cancer       Date:  2014-11-28       Impact factor: 4.430

5.  A comparison of treatment modalities for nasal extranodal natural killer/T-cell lymphoma in early stages: The efficacy of CHOP regimen based concurrent chemoradiotherapy.

Authors:  Jianzhong Cao; Shengmin Lan; Liuhai Shen; Hongwei Si; Ning Zhang; Hongwei Li; Ruyuan Guo
Journal:  Oncotarget       Date:  2017-03-21

6.  Prognostic significance of CD30 expression in nasal natural killer/T-cell lymphoma.

Authors:  Guan-Nan Wang; Wu-Gan Zhao; Ling Li; Dan-Dan Zhang; Xian-Zheng Gao; Jun Zhou; Lei Zhang; Xiao-Rui Fu; Xiang-Yu Zheng; Ye Li; Zhen Li; Ming-Zhi Zhang; Wen-Cai Li
Journal:  Oncol Lett       Date:  2017-01-11       Impact factor: 2.967

7.  CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China.

Authors:  Yanfen Feng; Huilan Rao; Yiyan Lei; Yuhua Huang; Fang Wang; Yu Zhang; Shaoyan Xi; Qiuliang Wu; Jianyong Shao
Journal:  Chin J Cancer       Date:  2017-05-10

8.  Histological vascular invasion is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type.

Authors:  Hua Wang; Pengfei Li; Xinke Zhang; Zhongjun Xia; Yue Lu; Huiqiang Huang
Journal:  Oncol Lett       Date:  2016-06-09       Impact factor: 2.967

9.  Hemoglobin level, a prognostic factor for nasal extranodal natural killer/T-cell lymphoma patients from stage I to IV: A validated prognostic nomogram.

Authors:  Jianzhong Cao; Shengmin Lan; Liuhai Shen; Hongwei Si; Huan Xiao; Qiang Yuan; Xue Li; Hongwei Li; Ruyuan Guo
Journal:  Sci Rep       Date:  2017-09-08       Impact factor: 4.379

10.  Clinical analysis of 42 cases of EBV-positive mature T/NK-cell neoplasms.

Authors:  Haiyan Yang; Gan Fu; Jia Liu; Zhenzhen Da; Xiaoye Cheng; Cong Chen; Yan Li; Bin Fu; Xiaolin Li
Journal:  Exp Ther Med       Date:  2017-06-01       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.